Paricalcitol + Calcitriol
Pre-clinicalTerminated 0 watching 0 views this week💤 Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Secondary Hyperparathyroidism
Conditions
Secondary Hyperparathyroidism, End-Stage Renal Disease
Trial Timeline
Jun 1, 2010 → May 1, 2012
NCT ID
NCT01134315About Paricalcitol + Calcitriol
Paricalcitol + Calcitriol is a pre-clinical stage product being developed by AbbVie for Secondary Hyperparathyroidism. The current trial status is terminated. This product is registered under clinical trial identifier NCT01134315. Target conditions include Secondary Hyperparathyroidism, End-Stage Renal Disease.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01134315 | Pre-clinical | Terminated |
Competing Products
20 competing products in Secondary Hyperparathyroidism
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ASP7991 + Cinacalcet + Placebo | Astellas Pharma | Phase 2 | 52 |
| Fycompa | Eisai | Pre-clinical | 23 |
| Fycompa | Eisai | Pre-clinical | 23 |
| KHK7580 + KRN1493 | Kyowa Kirin | Phase 2/3 | 65 |
| KHK7580 | Kyowa Kirin | Phase 1 | 33 |
| KHK7580 | Kyowa Kirin | Phase 3 | 77 |
| KHK7580 | Kyowa Kirin | Phase 3 | 77 |
| Cinacalcet HCl | Kyowa Kirin | Approved | 85 |
| KHK7580 + Cinacalcet Hydrochloride | Kyowa Kirin | Phase 3 | 77 |
| Placebo + KHK7580 low dose + KHK7580 middle dose + KHK7580 high dose + KRN1493 | Kyowa Kirin | Phase 2 | 52 |
| dirucotide + Placebo | Eli Lilly | Phase 2/3 | 65 |
| dirucotide | Eli Lilly | Phase 2/3 | 65 |
| paricalcitol + maxacalcitol + paricalcitol placebo + maxacalcitol placebo | AbbVie | Phase 3 | 77 |
| Paricalcitol + Calcifediol | AbbVie | Approved | 85 |
| Paricalcitol + Darbepoetin alfa | AbbVie | Approved | 85 |
| Birabresib Dose 20 mg | Merck | Phase 1 | 33 |
| Remibrutinib (blinded) + Placebo + Remibrutinib (Open label) | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Approved | 85 |
| BAF312 + Baseline disease modifying therapies (DMTs) + BNT162 + mRNA-1273 | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |